419 related articles for article (PubMed ID: 20197461)
1. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.
Xu Y; Stamenkovic I; Yu Q
Cancer Res; 2010 Mar; 70(6):2455-64. PubMed ID: 20197461
[TBL] [Abstract][Full Text] [Related]
2. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
[TBL] [Abstract][Full Text] [Related]
3. The role of CD44 in glioblastoma multiforme.
Mooney KL; Choy W; Sidhu S; Pelargos P; Bui TT; Voth B; Barnette N; Yang I
J Clin Neurosci; 2016 Dec; 34():1-5. PubMed ID: 27578526
[TBL] [Abstract][Full Text] [Related]
4. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
Xu Y; Wang K; Yu Q
Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
[TBL] [Abstract][Full Text] [Related]
5. Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.
Tran AN; Walker K; Harrison DG; Chen W; Mobley J; Hocevar L; Hackney JR; Sedaka RS; Pollock JS; Goldberg MS; Hambardzumyan D; Cooper SJ; Gillespie Y; Hjelmeland AB
Neuro Oncol; 2018 Jul; 20(8):1055-1067. PubMed ID: 29409010
[TBL] [Abstract][Full Text] [Related]
6. K-RAS Acts as a Critical Regulator of CD44 to Promote the Invasiveness and Stemness of GBM in Response to Ionizing Radiation.
Zhao Y; Kang JH; Yoo KC; Kang SG; Lee HJ; Lee SJ
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681583
[TBL] [Abstract][Full Text] [Related]
7. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Alafate W; Xu D; Wu W; Xiang J; Ma X; Xie W; Bai X; Wang M; Wang J
J Exp Clin Cancer Res; 2020 Nov; 39(1):239. PubMed ID: 33176854
[TBL] [Abstract][Full Text] [Related]
8. BCL6 promotes glioma and serves as a therapeutic target.
Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
[TBL] [Abstract][Full Text] [Related]
9. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.
Zhu H; Woolfenden S; Bronson RT; Jaffer ZM; Barluenga S; Winssinger N; Rubenstein AE; Chen R; Charest A
Mol Cancer Ther; 2010 Sep; 9(9):2618-26. PubMed ID: 20643786
[TBL] [Abstract][Full Text] [Related]
10. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
11. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells.
Hayward SL; Wilson CL; Kidambi S
Oncotarget; 2016 Jun; 7(23):34158-71. PubMed ID: 27120809
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.
Brunckhorst MK; Wang H; Lu R; Yu Q
Cancer Res; 2010 Sep; 70(18):7283-93. PubMed ID: 20823154
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
17. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
Bell JB; Eckerdt FD; Alley K; Magnusson LP; Hussain H; Bi Y; Arslan AD; Clymer J; Alvarez AA; Goldman S; Cheng SY; Nakano I; Horbinski C; Davuluri RV; James CD; Platanias LC
Mol Cancer Res; 2016 Oct; 14(10):984-993. PubMed ID: 27364770
[TBL] [Abstract][Full Text] [Related]
18. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model.
Andreou T; Williams J; Brownlie RJ; Salmond RJ; Watson E; Shaw G; Melcher A; Wurdak H; Short SC; Lorger M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707311
[TBL] [Abstract][Full Text] [Related]
20. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.
Jun F; Hong J; Liu Q; Guo Y; Liao Y; Huang J; Wen S; Shen L
Oncotarget; 2017 Feb; 8(9):14343-14358. PubMed ID: 27527869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
